Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.44 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16296251 | 1.00 | KMT2A (0.49) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL28015606 | 0.82 | MEN1 (0.51) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15416568 | 0.82 | MEN1 (0.51) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16307627 | 0.81 | MAPT (0.63) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1817848 | 0.78 | MEN1 (0.58) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL823725 | 0.77 | ALDH1A1 (0.58) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16296408 | 0.77 | LMNA (0.47) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10915040 | 0.76 | MAPT (0.47) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13448758 | 0.76 | GRM7 (0.54) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17086763 | 0.76 | GRM7 (0.54) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388177-B2 | Method for preparing substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-12 | — | — | US | claimed |
| US-20170342064-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-30 | — | — | US | disclosed |
| US-20170342064-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-30 | — | — | US | disclosed |
| EP-3230285-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-18 | — | — | EP | disclosed |
| EP-3008062-B1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma AG (DE) | 2017-04-05 | — | — | EP | disclosed |
| EP-3008062-B1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma AG (DE) | 2017-04-05 | — | — | EP | disclosed |
| US-9586958-B2 | Prodrug derivatives of substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-07 | — | — | US | disclosed |
| US-9586958-B2 | Prodrug derivatives of substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20150148542-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| US-20150148542-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| EP-2872506-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014198594-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014198647-A2 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014198647-A2 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014198594-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014195276-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014009219-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014009219-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | CMA1, TPP1, TPSAB1 | KMT2A 4262/4885MEN1 418/4885CYP1A2 624/4885 |
| US-20170342064-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | MPST, TK1, BRCA1 | KMT2A 3222/4885MEN1 712/4885CYP1A2 3471/4885 |
| US-20150148542-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | QDPR, CYP3A5, CYP3A7 | KMT2A 3947/4885MEN1 994/4885CYP1A2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.